Cargando…

An integrative analysis of Qingfei Paidu Decoction for its anti-HCoV-229E mechanism in cold and damp environment based on the pharmacokinetics, metabolomics and molecular docking technology

BACKGROUND: The novel coronavirus pneumonia (COVID-19) has spread rapidly around the world. As a member against the epidemic, Qingfei Paidu Decoction (QFPDD) has been approved for the treatment of COVID-19 in China. However, its antiviral mechanism was still largely unclear. PURPOSE: An integrated s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Yan, Gu, Xinru, Zhou, Yanyan, Si, Nan, Gao, Wenya, Sun, Bo, Sun, Jing, Li, Tao, Wang, Linna, Wei, Xiaolu, Guo, Shanshan, Cui, Xiaolan, Bian, Baolin, Wang, Hongjie, Wang, Liang, Zhao, Haiyu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier GmbH. 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9605917/ https://www.ncbi.nlm.nih.gov/pubmed/36332393 http://dx.doi.org/10.1016/j.phymed.2022.154527

Ejemplares similares

Qingfei Paidu Decoction for COVID-19: A Bibliometric Analysis
por: LIU, Si Hong, et al.
Publicado: (2021)

Research Advance on Qingfei Paidu Decoction in Prescription Principle, Mechanism Analysis and Clinical Application
por: Ren, Wei, et al.
Publicado: (2021)

Adaptation of the endemic coronaviruses HCoV-OC43 and HCoV-229E to the human host
por: Forni, Diego, et al.
Publicado: (2021)

HCoV-229E Infects and Activates Monocytes
por: Desforges, Marc, et al.
Publicado: (2006)

Titration of Human Coronaviruses, HCoV-229E and HCoV-OC43, by an Indirect Immunoperoxidase Assay
por: Lambert, Francine, et al.
Publicado: (2007)

Heparan Sulfate and Enoxaparin Interact at the Interface of the Spike Protein of HCoV-229E but Not with HCoV-OC43
por: Fuochi, Virginia, et al.
Publicado: (2023)

Structural characterization of the HCoV-229E fusion core
por: Zhang, Wei, et al.
Publicado: (2018)

Effect of Qingfei Paidu decoction combined with Western medicine treatments for COVID-19: A systematic review and meta-analysis
por: Zhang, Lei, et al.
Publicado: (2022)

Efficacy and Safety of Qingfei Paidu Decoction for Treating COVID-19: A Systematic Review and Meta-Analysis
por: Wang, Qi, et al.
Publicado: (2021)

Clinical retrospective study on the efficacy of Qingfei Paidu decoction combined with Western medicine for COVID-19 treatment
por: Xin, Siyi, et al.
Publicado: (2020)

Mouse models susceptible to HCoV-229E and HCoV-NL63 and cross protection from challenge with SARS-CoV-2
por: Liu, Donglan, et al.
Publicado: (2023)

Identification of phytochemicals in Qingfei Paidu decoction for the treatment of coronavirus disease 2019 by targeting the virus-host interactome
por: Li, Yuyun, et al.
Publicado: (2022)

Seasonality and immunity to laboratory-confirmed seasonal coronaviruses (HCoV-NL63, HCoV-OC43, and HCoV-229E): results from the Flu Watch cohort study
por: Aldridge, Robert W., et al.
Publicado: (2020)

Inhibition of drug-metabolizing enzymes by Qingfei Paidu decoction: Implication of herb-drug interactions in COVID-19 pharmacotherapy
por: Zhang, Feng, et al.
Publicado: (2021)

Efficacy of Qingfei Paidu Decoction on Patients with COVID-19 Pneumonia in Wuhan, China: A Propensity Score Matching Study
por: Liu, Zhen, et al.
Publicado: (2021)

Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506
por: Carbajo-Lozoya, Javier, et al.
Publicado: (2012)

Protection against COVID-19 injury by qingfei paidu decoction via anti-viral, anti-inflammatory activity and metabolic programming
por: Chen, Jian, et al.
Publicado: (2020)

The human coronavirus HCoV-229E S-protein structure and receptor binding
por: Li, Zhijie, et al.
Publicado: (2019)

Network pharmacology and computer-aided drug design to explored potential targets of Lianhua Qingwen and Qingfei Paidu decoction for COVID-19
por: Li, Liyuan, et al.
Publicado: (2022)

Characterization of HCoV-229E fusion core: Implications for structure basis of coronavirus membrane fusion
por: Liu, Cheng, et al.
Publicado: (2006)

Qingfei Paidu decoction for treating COVID-19: A protocol for a meta-analysis and systematic review of randomized controlled trials
por: Zhang, Yuan, et al.
Publicado: (2020)

Chemical composition and pharmacological mechanism of Qingfei Paidu Decoction and Ma Xing Shi Gan Decoction against Coronavirus Disease 2019 (COVID-19): In silico and experimental study
por: Yang, Ruocong, et al.
Publicado: (2020)

Association between early treatment with Qingfei Paidu decoction and favorable clinical outcomes in patients with COVID-19: A retrospective multicenter cohort study
por: Shi, Nannan, et al.
Publicado: (2020)

Fatal human coronavirus 229E (HCoV-229E) and RSV–Related pneumonia in an AIDS patient from Colombia
por: Villamil-Gómez, Wilmer E., et al.
Publicado: (2020)

Structural basis of main proteases of HCoV-229E bound to inhibitor PF-07304814 and PF-07321332
por: Zhou, Yanru, et al.
Publicado: (2023)

Pan-Coronavirus CRISPR-CasRx Effector System Significantly Reduces Viable Titer in HCoV-OC43, HCoV-229E, and SARS-CoV-2
por: Mayes, Cathryn M., et al.
Publicado: (2023)

Comparative Antiviral Activity of Remdesivir and Anti-HIV Nucleoside Analogs against Human Coronavirus 229E (HCoV-229E)
por: Parang, Keykavous, et al.
Publicado: (2020)

Cryo-EM analysis of the HCoV-229E spike glycoprotein reveals dynamic prefusion conformational changes
por: Song, Xiyong, et al.
Publicado: (2021)

Resveratrol Inhibits HCoV-229E and SARS-CoV-2 Coronavirus Replication In Vitro
por: Pasquereau, Sébastien, et al.
Publicado: (2021)

Coronavirus humains (HCoV)
por: Vabret, A., et al.
Publicado: (2009)

The therapeutic promises of Lianhuaqingke in the mice model of coronavirus pneumonia (HCoV-229E and SARS-CoV-2)
por: Wang, Mingye, et al.
Publicado: (2021)

Treatment Effect of Qingfei Paidu Decoction Combined With Conventional Treatment on COVID-19 Patients and Other Respiratory Diseases: A Multi-Center Retrospective Case Series
por: Zong, Xingyu, et al.
Publicado: (2022)

Transcriptomic profiling and genomic mutational analysis of Human coronavirus (HCoV)-229E -infected human cells
por: Friedman, Nehemya, et al.
Publicado: (2021)

Antiviral Activity of Ficus rubiginosa Leaf Extracts against HSV-1, HCoV-229E and PV-1
por: Dell’Annunziata, Federica, et al.
Publicado: (2022)

Ferulic acid derivatives block coronaviruses HCoV-229E and SARS-CoV-2 replication in vitro
por: Pasquereau, Sébastien, et al.
Publicado: (2022)

Traditional Chinese Medicine, Qingfei Paidu Decoction and Xuanfei Baidu Decoction, Inhibited Cytokine Production via NF-κB Signaling Pathway in Macrophages: Implications for Coronavirus Disease 2019 (COVID-19) Therapy
por: Li, Yujia, et al.
Publicado: (2021)

Corrigendum to ’Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506’ Virus Research (2012) 165/1 [112-117]: Corrigendum
por: Carbajo-Lozoya, Javier, et al.
Publicado: (2022)

Peptide-Based Membrane Fusion Inhibitors Targeting HCoV-229E Spike Protein HR1 and HR2 Domains
por: Xia, Shuai, et al.
Publicado: (2018)

Effectiveness and safety research of Qingfei Paidu (QFPD) in treatment of COVID-19: an up-to-date systematic review and meta-analysis
por: Wang, Xinxin, et al.
Publicado: (2022)

Computer-aided drug design combined network pharmacology to explore anti-SARS-CoV-2 or anti-inflammatory targets and mechanisms of Qingfei Paidu Decoction for COVID-19
por: Wang, Zixuan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_13a7jlolcv4745kt0m1upppgtm